Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Microport Cardioflow Medtech
Its shares trade on HKEX under the ticker 2160.HK. It has been listed since 4 February 2021. In the fiscal year to 31 December 2024, it reported revenue of CN¥361.6m and a net loss of CN¥49.4m. At that date it held total assets of CN¥2.68bn and shareholders' equity of CN¥2.19bn.
MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The firm is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The firm's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The firm mainly conducts business within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 4 Feb 2021
- Employees
- 579
- Website
- cardioflowmedtech.com ↗
Leadership
Pay as last reported
- Mr. Guoming ChenNon-Executive Chairman of the Board, since 2020HK$3.8m
- Mr. Jeffrey LindstromPresident, Executive Director
- Ms. Luying YanVice President, Executive Director, since 2020HK$3.0m
- Mr. Liang ZhaoExecutive Director, since 2021
- Ms. Lok Yee ChanJoint Company Secretary
- Ms. Xiangmei LiJoint Company Secretary
- Ms. Xia WuNon-Executive Director
- Mr. Junjie ZhangNon-Executive Director
- Dr. Jiandong DingIndependent Non-Executive DirectorHK$69,000
- Ms. Zhixiang SunIndependent Non-Executive DirectorHK$192,000
- Mr. Jiahong ZhouIndependent Non-Executive DirectorHK$192,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MicroPort Cardioflow Medtech Corp. develops TAVI products VitaFlow and VitaFlow II for valvular heart diseases.
- The company employs 579 full-time employees focused on medical device innovation in Shanghai.
- MicroPort Cardioflow Medtech Corp. operates as a holding company with a strong domestic market presence.
Weaknesses
- The company's business is primarily limited to the domestic market in China.
- MicroPort Cardioflow Medtech Corp. has no international expansion mentioned in its business description.
- The firm relies solely on TAVI products without diversification into other medical device segments.
Opportunities
- Expanding TAVI product lines could increase market share in China's growing health care sector.
- The domestic market in China offers significant growth potential for medical device companies.
- MicroPort Cardioflow Medtech Corp. could leverage its Shanghai headquarters for international partnerships.
Threats
- Competition from domestic medical device companies in China's health care sector.
- Regulatory changes in China's health care industry could impact product approvals.
- Dependence on TAVI products may limit growth if market demand shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.